CLS Special Populations in Lipid Management Flashcards

In patients with non-alcoholic fatty liver disease (NAFLD), which statement best describes statin use?

Answer: Statins are safe and may even benefit liver histology in NAFLD patients

Evidence supports that statins are safe in NAFLD and observational data suggests they may improve liver histology, with NAFLD not considered a contraindication.

In the setting of acute coronary syndrome (ACS), when should high-intensity statin therapy be initiated?

Answer: As soon as possible, prior to or during hospital discharge regardless of baseline LDL-C

Current guidelines recommend initiating high-intensity statin therapy in ACS patients as early as possible, regardless of baseline LDL-C, due to pleiotropic and lipid-lowering benefits.

Which lipid parameter is most significantly affected by significant weight loss (≥10% body weight) achieved through lifestyle intervention?

Answer: Triglycerides show the greatest proportional reduction, often exceeding 30%

Weight loss of ≥10% disproportionately reduces triglycerides, often by 30–50%, because visceral fat reduction decreases hepatic free fatty acid delivery and VLDL production.

In patients with systemic lupus erythematosus (SLE), what is the primary driver of accelerated cardiovascular disease and dyslipidemia?

Answer: Chronic inflammation, corticosteroid use, and immune complex deposition in vessels

In SLE, accelerated atherosclerosis is driven by chronic inflammation, corticosteroid-induced dyslipidemia, and immune-mediated vascular damage, all requiring aggressive lipid management.

In a patient with familial hypercholesterolemia who becomes pregnant, which lipid-lowering option is considered safe during pregnancy?

Answer: Bile acid sequestrants (cholestyramine, colestipol)

Bile acid sequestrants are not systemically absorbed and are considered the safest option for lipid lowering during pregnancy in patients with FH.

In patients with type 2 diabetes at high cardiovascular risk, what is the recommended LDL-C goal according to the 2018 AHA/ACC guidelines?

Answer: <70 mg/dL with maximally tolerated statin therapy

The 2018 AHA/ACC guidelines recommend an LDL-C goal of <70 mg/dL with maximally tolerated statin therapy for patients with diabetes and high cardiovascular risk.